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Background: Clinical studies have shown that the use of certain drugs can reduce disability. Access to
prescription drugs varies across countries. Even when the total number of drugs launched in two
countries is similar, the specific drugs that were launched, and the diseases those drugs are used to treat,
may differ.
Objective/Hypothesis: We test the hypothesis that the larger the relative number of drugs for a disease
that were launched during 1982e2015 in a country, the lower the relative disability in 2015 of patients
with that disease in that country, controlling for the average level of disability in that country and from
that disease, and the number of patients with the disease and their mean age.
Methods: We estimate two-way (by country and disease) fixed-effects models of several measures of
disability for 31 diseases in eleven European countries using data from the Survey of Health, Ageing and
Retirement in Europe and from other sources.
Results: The estimates imply that drug launches during 1982e2015 reduced the probability of severe
limitation in 2015 by 4.9 percentage points, from 21.8% to 16.9%; they reduced the probability of any
limitation by 7.7 percentage points, from 61.1% to 53.4%; and they reduced the mean number of Activities
of Daily Living limitations by about 29%. Drug launches also yielded a small increase in an index of quality
of life and well-being.
Conclusions: In general, the larger the number of drugs for a disease that were launched during 1982
e2015 in a country, the lower the average disability in 2015 of patients with that disease in that country,
controlling for the average level of disability in that country and from that disease, and the number of
patients with the disease and their mean age.
© 2019 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Clinical studies have shown that the use of certain drugs can
reduce disability. Nevitt et (2000)1 showed that in postmenopausal
womenwith preexisting vertebral fracture, alendronate therapy for
3 years reduced the number of days of bed disability and days of
limited activity caused by back pain. Filippini et al. (2014)2
demonstrated that etanercept, adalimumab, and infliximab
reduced disability in rheumatoid arthritis patients, even those with
a longstanding history and highly-active form of the disease.
Andalo (2016)3 showed that multiple sclerosis patients given
alemtuzumab (first launched in 2001) were almost twice as likelync. This is an open access article un
e impact of access to prescrip
.2019.01.003to achieve an improvement in physical disabilities as those given
interferon beta-1a (first launched in 1995).
Access to prescription drugs varies across countries. Fig. 1 shows
the number of new chemical entities (NCEs) that were launched in
eleven European countries during the period 1982e2015. The
average number of NCEs launched in the top 3 countries (709) was
42% higher than the number of NCEs launched in the bottom 3
countries (501). Even when country A had more launches than
country B, country A may have had fewer drugs launched for some
diseases. As shown in Fig. 2, at least twomore drugs were launched
in Italy than in Spain for four diseases, and at least two fewer drugs
were launched in Italy for three other diseases.
This study will empirically investigate two hypotheses about
relative access to prescription drugs for different diseases in
different countries. The first hypothesis is about the determinants of
relative access. The hypothesis is that the greater the relativeder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
tion drugs on disability in eleven European countries, Disability and
Fig. 1. Number of New Chemical Entities launched during 1982e2015, by country.
F.R. Lichtenberg / Disability and Health Journal xxx (xxxx) xxx2prevalence of a disease in a country, the larger the relative number
of drugs for the disease that will be launched in the country. The
second hypothesis is about the consequences of relative access. The
hypothesis is that the larger the relative number of drugs for a
disease that have been launched in a country,1 the lower the rela-
tive disability of patients with that disease in that country, con-
trolling for several other factors. As shown in Fig. 3, relative
disability from different diseases varies across countries: French
people who had had chronic kidney disease and hip fractures were
more likely to be severely limited than Germans, but French people
who had had ulcers, breast cancer, and strokes were less likely to be
severely limited than Germans.1 International differences in drug expenditure are not meaningful indicators of
international differences in access to drugs due to substantial variation in drug
prices. For example, in 2017 the price of the hepatitis C drug Harvoni was over 200
times as high in the U.S. as it was in Egypt. See Civio (2017)4 and Lichtenberg
(2010).5
2 Lichtenberg (2018)6 employed a similar methodology (two-way fixed effects
model of different diseases in different countries). That study differs from this study
in several major ways, including the following:








Survey of Health, Ageing and
Retirement in Europe (SHARE)
WHO Global Health
Estimates 2015
Please cite this article as: Lichtenberg FR, The impact of access to prescrip
Health Journal, https://doi.org/10.1016/j.dhjo.2019.01.003Both of these hypotheses will be tested using a two-way, fixed-
effects, cross-sectional research design, based on group-level data
on 31 diseases in 11 countries derived fromWave 6 of the Survey of
Health, Ageing and Retirement in Europe (SHARE) and other
sources. The models we will estimate will include both country
fixed effects and disease fixed effects, which control for the average
level of disability (and the average number of drug launches) in
each country and for each disease.2 Several alternative (self-re-
ported) measures of disability (and quality of life) will be analyzed,
including the fraction of people with severe limitations or any
limitations, and the number of activities of daily living limitations.
In the next section, we describe econometric models of the
determinants and consequences of relative prescription drug ac-
cess, and data sources and descriptive statistics. Empirical results
are presented in Section III. Implications of the estimates are dis-
cussed in Section IV. Section V provides a summary and
conclusions.Methods
Model of the effect of disease prevalence on the number of drug
launches
Previous studies have shown that both innovation (the number
of drugs developed) and diffusion (the number of drugs launched in
a country) depend on market size. Acemoglu and Linn (2004)7
found “economically significant and relatively robust effects oftion drugs on disability in eleven European countries, Disability and
Fig. 2. Difference between number of drugs launched during 1982e2015 for 7 diseases in Italy and Spain.
F.R. Lichtenberg / Disability and Health Journal xxx (xxxx) xxx 3market size on innovation.” Danzon et al. (2005)8 found that
“countries with lower expected prices or smaller expected market
size experience longer delays in new drug access, controlling for per
capita income and other country and firm characteristics”
(emphasis added).
The hypothesis that the number of drug launches is influenced
by market size can be investigated in a two-way fixed-effects
framework by estimating the following equation:
LAUNCHES_2006_2015dc¼ s ln(PREV_2005dc) þ ad þ dc þ εdc (1)
where
LAUNCHES_2006_2015dc¼ the number of drugs to treat disease
d launched in country c during 2006e2015
PREV_2005dc¼ the number of patients in country c in 2005who
had ever been told by a doctor that they had disease d
ad¼ a fixed effect for disease d
pc¼ a fixed effect for country c3 The CASP index was designed to cover the active and beneficial experiences of
later life rather than simply focus on the medical and social care issues that had
traditionally been seen to typify ageing research. The scale is composed of 4 sub-
scales, the initials of which make up the acronym: Control, Autonomy, Self-Reali-
zation and Pleasure. https://casp19.com/background/See also Hyde et al. (2003)9
and Howel (2012).10
4 Our data on drug launches are left-censored: we only have data on drugs
launched after 1981. A post-1981 new chemical entity is one that was first launched
anywhere in the world after 1981.Model of the effect of the number of drug launches on disability
The basic model we will estimate to investigate the effect of
prescription drug access on disability is:
Ydc¼ b0-33 LAUNCHES_1982_2015dc þ g ln(PREVdc) þ r
AGE_MEANdc þ L1 OVERWEIGHT%dc þ L2 OBESE
%dc þ ad þ pc þ εdc (2)
where Ydc is one of the following variables:Please cite this article as: Lichtenberg FR, The impact of access to prescrip
Health Journal, https://doi.org/10.1016/j.dhjo.2019.01.003ln(limit_severe%dc/(1 e limit_severe%dc))¼ the log-odds that
individuals with disease d in country c in 2015 have severe
limitations
ln(limit_any%dc/(1 e limit_any%dc))¼ the log-odds that in-
dividuals with disease d in country c in 2015 have any
limitations
N_ADLdc¼ the mean number of limitations with activities of
daily living of individuals with disease d in country c in 2015
N_IADLdc¼ the mean number of limitations with instrumental
activities of daily living of individuals with disease d in country c
in 2015
CASPdc¼ the mean CASP index3 for quality of life and well-being
of individuals with disease d in country c in 2015
and
LAUNCHES_1982_2015dc¼ the number of post-19814 new
chemical entities used to treat disease d launched in country c
during 1982e2015
PREVdc¼ the number of people in country c in 2015 who said
that a doctor ever told them that they had disease dtion drugs on disability in eleven European countries, Disability and
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Pl
HAGEdc¼ the mean age of people in country c in 2015 who said
that a doctor ever told them that they had disease d
OVERWEIGHT%dc¼ the fraction of people with disease d in
country c in 2015 who were overweightDependent variable Weight8
ln(limit_severe%dc/(1 e limit_severe%dc)) PREV_ADJdc * limit_severe%dc * (1 e limit_severe%dc)
ln(limit_any%dc/(1 e limit_any%dc)) PREV_ADJdc * limit_any%dc * (1 e limit_any%dc)
N_ADLdc PREV_ADJdc
N_IADLdc PREV_ADJdc
CASPdc PREV_ADJdcOBESE%dc¼ the fraction of people with disease d in country c in
2015 who were obese5
A person is considered to have a disease if he or she said that a
doctor had ever told them that they had the disease. Sixty percent
of individuals in the sample who had at least one disease had more
than one disease. From the survey, we knowwhether someone was
disabled, but we don't know which medical conditions caused the
disability.6 We will account for this in the following way: an indi-
vidual with N diseases will contribute N observations (one for eachArmour et al. (2012)11 documented "high prevalence of disability among those
o are obese."
In contrast, the U.S. Medical Expenditure Panel Survey provides some infor-
tion about the specific causes of activity limitations.
Weighting the observations in this way does not have a significant impact on
estimates of eq. (2).
ease cite this article as: Lichtenberg FR, The impact of access to prescrip
ealth Journal, https://doi.org/10.1016/j.dhjo.2019.01.003disease), but each observation will be given a weight of (1/N).7 Eq.
(2) will be estimated by weighted least squares; the disturbances
will be clustered within countries or within diseases. The following
weights will be used:PREV_ADJdc is the “adjusted prevalence” of disease d in country
c. Let HAS_DISEASEidc¼ 1 if person i in country c has disease d,
and¼ 0 if person i in country c does not have disease d. The number
of diseases patient i has is N_DISEASESi.c¼
P
d HAS_DISEASEidc.
The prevalence of disease d in country c is PREVdc¼
P
i HAS_-





The indicator in eq. (2) of prescription drug access in 2015 of
patients with disease d in country c is the number of post-1981 new8 The first two weights are based on the fact that the variance of the binomial
distribution with parameters n and p (where n is the number of trials and p is the
“success” probability) is n * p * (1 - p).
tion drugs on disability in eleven European countries, Disability and
Fig. 4. Effect of disease screening/awareness on measured prevalence and mean severity.
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during 1982e2015.9 The launch of a drug in a country indicates that
patients could have been treated with that drug, not necessarily
that patients were treated with that drug. We would prefer to es-
timate models in which the explanatory variables measured the
drugs actually used to treat patients, by disease and country. We
have 2015 data on the utilization of each drug in each country.
However, many drugs have multiple indicationsd48% of drugs
have 2 or more indications (causes of disability), and 8% of drugs
have 6 or more indicationsdand our data do not enable us to
determine how often each drug was used for each of its indications.
In eq. (2), the number of drugs launched at different times
during 1982e2015 (e.g. before and after 2000) are constrained to
have equal effects on disability in 2015. It is possible, however, that
the effect of more recently-launched drugs could differ from the
effect of drugs launched longer ago. The effect of a drug's launch on
disability is likely to depend on both the quantity and the quality (or
effectiveness) of the drug. Indeed, it is likely to depend on the
interaction between quantity and quality: a quality improvement
will have a greater impact on disability if drug utilization (quantity)
is high. Drugs launched in different periods are likely to vary (in
opposite ways) with respect to both quantity (in 2015) and quality.
Newer drugs are likely to be of higher quality than older drugs.10 On
the other hand, utilization of new drugs tends to be much lower
than utilization of old drugs.11 To allow for the possibility that drugs
launched at different times during 1982e2015 had different effects9 More than a dozen studies published in high-quality peer-reviewed journals
(e.g. Refs.6,12e14) have examined the impact of drug launches on mortality. Also, a
study based on U.S. data15 showed that growth in the mean number of pre-
scriptions for new (post-1990) drugs consumed for a medical condition is strongly
related to growth in the (lagged) cumulative number of drugs launched for the
condition and not related to changes in the socioeconomic status (income, edu-
cation, or race) of people with the condition.
10 Grossman and Helpman (1993)16 argued that “innovative goods are better than
older products simply because they provide more ‘product services’ in relation to
their cost of production.” Bresnahan and Gordon (1996)17 stated simply that “new
goods are at the heart of economic progress,” and Bils (2004)18 said that “much of
economic growth occurs through growth in quality as new models of consumer
goods replace older, sometimes inferior, models.” As noted by Jovanovic and Yat-
senko (2012),19 in “the SpenceeDixiteStiglitz tradition… new goods [are] of higher
quality than old goods.”
11 For example, a previous study [6] showed that mean utilization of a cancer drug
is about twice as high 5e9 years after launch as it was 0e4 years after launch.
Please cite this article as: Lichtenberg FR, The impact of access to prescrip
Health Journal, https://doi.org/10.1016/j.dhjo.2019.01.003on disability in 2015, we will also estimate two more general ver-
sions of eq. (2).12 In the first version, we differentiate between the
number of launches in 3 periods, by replacing (b0-33 LAUN-
CHES_1982_2015dc) in eq. (2) with (b0-9 LAUNCHES_2006_
2015dc þ b10-19 LAUNCHES_1996_2005dc þ b20-33 LAUN-
CHES_1982_1995dc). In the second version, we differentiate be-
tween the number of launches in 4 periods, by replacing (b0-33
LAUNCHES_1982_2015dc) in eq. (2) with (b0-4 LAUNCHES_2011_
2015dc þ b5-9 LAUNCHES_2006_2010dc þ b10-14 LAUNCHES_2001_
2005dc þ b15-33 LAUNCHES_1982_2000dc). We will compare the
overall effect of drug launches in the three different versions of the
model. In eq. (2), the impact is b0-33 * mean(-
LAUNCHES_1982_2015dc); in the model that differentiates between
the number of launches in 4 periods, the impact is (b0-4 *
mean(LAUNCHES_2011_2015dc) þ b5-9 * mean(-
LAUNCHES_2006_2010dc)þ b10-14 * mean(LAUNCHES_2001_
2005dc) þ b15-33 * mean(LAUNCHES_1982_2000dc)).
The disease prevalence variable (ln(PREVdc)) is included as a
regressor in eq. (2) to control for potential variation in disease
screening intensity or awareness. Suppose that the severity of a
disease is normally distributed, as depicted in Fig. 4. If disease
screening/awareness is low, only the most severe cases (those with
severity S> S0) will be detected and reported, and mean disability
from the disease will be high. If disease screening/awareness is
high, less severe cases (those with severity S> S1) will be detected
and reported, and mean disability from the disease will be lower.
Hence one would expect that the higher the relative reported
prevalence of a disease, the lower the relative mean disability from
the disease. As discussed above, higher (true or measured) disease
prevalence is also likely to cause more drug launches. Therefore, as
shown in Fig. 5, failure to control for prevalence could bias esti-
mates of the drug launch coefficients away from zero. On the other
hand, controlling for prevalence may make our estimates of the12 However, our ability to distinguish between the effects of launches in different
periods will be limited by (negative) serial correlation in drug launches, which
results in multicollinearity between the number of launches in different periods.
This serial correlation is evident from estimates of the following model:
LAUNCHES_2001_2015dc¼u LAUNCHES_1982_2000dc þ ad þ pc þ εdc. The esti-
mate of u is negative and highly significant: estimate¼0.29; Z¼ 4.77; p-
value< .0001. The larger the relative number of drugs launched during 1982e2000,
the smaller the relative number of drugs launched during 2001e2015.
tion drugs on disability in eleven European countries, Disability and
Fig. 5. Effect of (measured) prevalence on number of drug launches and mean
disability.
F.R. Lichtenberg / Disability and Health Journal xxx (xxxx) xxx6drug launch coefficients to be conservative. Targeted efforts and
programs to reduce disease burden are likely to depend on disease
prevalence, so controlling for prevalence will also control at least to
some extent for the effects of those efforts and programs on
disability.
The fixed effects in eq. (2) control for many unobserved po-
tential determinants of disability. The disease fixed effects (ad's)
control for the fact that (for example) average disability from
chronic kidney disease is higher than average disability from ulcers.
The country fixed effects (pc's) control for a country's attributes
(e.g. its average income, educational attainment, and health care
expenditure) to the extent that they have similar effects on
disability from different diseases.13
Data sources and descriptive statistics
Data on disability were obtained from Wave 6 of the Survey of
Health, Ageing and Retirement in Europe (SHARE), a multidisci-
plinary and cross-national panel database of micro data on health,
socio-economic status and social and family networks of more than
120,000 individuals aged 50 or older.20 The fieldwork of Wave 6
was completed in November 2015. Although SHARE covers 27 Eu-
ropean countries and Israel, data on drug launches since 1982 were
available for only eleven of those countries.14
Summary statistics, by country, are shown in Table 1. The totalTable 1













45592 67.8 1.6 13% 43%
Austria 3402 69.1 1.5 17% 50%
Belgium 5823 66.4 1.7 16% 48%
Denmark 3733 65.6 1.3 9% 38%
France 3948 68.0 1.6 16% 46%
Germany 4412 66.3 1.7 18% 55%
Greece 4937 66.8 1.6 8% 30%
Italy 5313 67.2 1.4 14% 40%
Portugal 1676 67.7 2.3 23% 60%
Spain 5636 70.0 1.7 7% 40%
Sweden 3906 70.4 1.3 13% 44%
Switzerland 2806 68.6 1.1 9% 35%
13 For example, suppose that Ydc depends on EDUc (where EDUc¼ average
educational attainment in country c), and that pcdthe marginal effect of EDUc on
Ydcddoes not vary across diseases (pc¼p, all c). Then pc EDUc¼p EDUc, which
may be written as pc.
14 Data on medical condition prevalence in 2005 (used to estimate eq. (1)) were
obtained from Wave 1 of SHARE.
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and their mean age was 67.8. The average number of medical
conditions reported (including persons with no medical condi-
tions) was 1.6. Thirteen percent of respondents indicated that they
were severely limited, and 43% indicated that they had either a
severe or mild limitation. The mean number of ADL and IADL
limitations reported were 0.3 and 0.5, respectively.
Summary statistics, by medical condition, are shown in Table 2.
Two cardiovascular conditions (I10 hypertension and E78 high
cholesterol) were the most prevalent by far. However, disability
associated with these conditions was lower than disability associ-
ated with other medical conditions. Ten percent of people with
either of the two cardiovascular conditions were severely limited,
whereas 17% of people with all conditions were severely limited.
Therefore, although the number of people who had hypertension
was almost twice as great as the number who had osteoarthritis,
the weight given to hypertension in the ln(limit_severe%dc/(1 e
limit_severe%dc)) model is only 28% larger than the weight given to
osteoarthritis.
Data on the number of SHARE Wave 6 respondents who re-
ported that they had eachmedical condition, by country, are shown
in Appendix Table 1.
Data on drug launch years, by molecule and country, were ob-
tained from the IMS HealthNew Product Focus database. Data on the
indications of each drug were obtained from the Theriaque data-
base.21,15 Data on the number of drugs launched during 1982e2015,
by country and medical condition, are shown in Table 3.Results
Estimate of model of the effect of disease prevalence on the number
of drug launches
The estimate of s, the ln(PREV_2005dc) coefficient in the model
of the effect of disease prevalence on the number of drug launches
(eq. (1)), is positive and significant: estimate¼ 0.366; standard er-
ror¼ 0.162; Z¼ 2.26; p-value¼ .0237. This signifies that larger
relative market size (number of patients diagnosed) increases the




















15 The Theriaque database provides data on labeled indications, not on unlabeled
indications. To the extent that drugs are used off-label, the drug launch variables in
eq. (2) are measured with error. If this measurement error is random, it is likely to
bias estimates of the drug launch coefficients towards zero.
tion drugs on disability in eleven European countries, Disability and
Table 2
Summary statistics, by medical condition.








mean number of ADL
limitations
mean number of IADL
limitations




62,424 69.7 17% 54% 0.36 0.73 36.4
C00-C14 cancer oral
cavity
27 73.7 37% 65% 0.75 1.15 35.9
C15 cancer oesophagus 15 72.0 46% 81% 1.16 2.40 34.8
C16 cancer stomach 71 69.3 39% 87% 0.68 1.27 34.1
C18-C20 cancer colon
or rectum
194 70.3 32% 72% 0.28 0.56 37.1
C22 cancer liver 62 69.5 39% 83% 0.40 0.96 34.8
C25 cancer pancreas 31 71.4 54% 65% 1.19 2.15 32.5
C34 cancer lung 116 71.2 52% 90% 0.34 0.98 33.8
C43-C44 cancer skin 160 68.3 17% 48% 0.22 0.44 39.1
C50 cancer breast 495 66.2 23% 62% 0.28 0.56 36.5
C53 cancer cervix 64 67.7 40% 71% 0.53 0.90 33.9
C56 cancer ovary 58 66.7 34% 62% 0.64 1.23 36.8
C61 cancer prostate 369 73.4 22% 61% 0.34 0.64 37.2
C64 cancer kidney 65 70.3 17% 53% 0.29 0.42 37.7
C67 cancer bladder 82 70.0 31% 67% 0.37 0.64 37.2
C71 cancer brain 39 68.8 30% 97% 1.11 2.11 35.9
C73 cancer thyroid 57 65.0 16% 71% 0.18 0.44 36.0
C82-C85 cancer NHL 60 71.1 36% 68% 0.42 0.75 38.1
C91-C95 cancer
leukaemia
60 69.7 22% 54% 0.54 0.76 37.1
E10-E14 diabetes 5717 70.2 16% 53% 0.34 0.68 36.2
E78 high cholesterol 11,080 68.0 10% 39% 0.18 0.39 37.1
G20 parkinson disease 405 75.2 47% 84% 1.54 2.61 33.4
G30 alzheimer 1057 81.3 60% 89% 2.30 5.23 32.1
I10 hypertension 17,438 69.2 10% 41% 0.21 0.44 37.3
I21-I23 heart attack 4581 73.0 24% 68% 0.42 0.92 35.8
I63-I64 stroke 1571 73.1 43% 78% 1.24 2.34 34.6
J40eJ47 chronic lung 2883 68.9 25% 70% 0.39 0.82 35.7
K25-K27 ulcer 1626 66.6 17% 54% 0.35 0.62 34.6
M05-M06 rheumatoid
arthritis
3603 70.4 20% 68% 0.41 0.83 35.1
M15-M19
osteoarthritis
8858 68.9 17% 63% 0.30 0.58 36.8
N18 chronic kidney 720 71.2 32% 74% 0.64 1.25 34.3
S72 hip fracture 860 75.0 34% 71% 0.91 1.62 34.8
F.R. Lichtenberg / Disability and Health Journal xxx (xxxx) xxx 7finding is broadly consistent with the notion that “misery loves
company” (Lichtenberg and Waldfogel (2009)22): the relative
number of drugs launched for a disease in a country is higher when
the relative prevalence of that disease is greater.
Estimates of model of the effect of the number of drug launches on
disability
Estimates of the model of the effect of the number of drug
launches on disability (eq. (2)) are presented in Table 4. All models
include disease fixed effects and country fixed effects, but to
conserve space, estimates of these parameters are not shown in
Table 4. Complete estimates of one model (the model of the log-
odds of severe limitation) are shown in Appendix Table 2.
In column 1 of Table 4, the dependent variable is the log-odds of
severe limitation. The coefficient on LAUNCHES_1982_2015 is
negative and highly significant (p-value¼ .004), which signifies
that the larger the relative number of drugs launched during
1982e2015, the lower were the relative odds of severe limitation in
2015. The impact of drug launches on the log-odds of severe limi-
tation (b0-33 * mean(LAUNCHES_1982_2015dc)), was 0.317. This
signifies that drug launches during the entire 1982e2015 period
reduced the log-odds of severe limitation in 2015 by 27% (¼ 1 e
exp(-0.317)). The coefficient on ln(PREV) is negative and signifi-
cant; this may be due to the effects of disease screening/awarenessPlease cite this article as: Lichtenberg FR, The impact of access to prescrip
Health Journal, https://doi.org/10.1016/j.dhjo.2019.01.003on measured prevalence and mean disability. The coefficient on
AGE_MEAN is positive and significant; older people are more likely
to have severe limitations. The coefficient on OVERWEIGHT% is also
positive and significant, but the coefficient on OBESE% is
insignificant.
In column 2 of Table 4, the dependent variable is the log-odds of
any (severe or mild) limitation. The estimates of this model are very
similar to the estimates in column 1. Drug launches during the
entire 1982e2015 period are also estimated to have reduced the
log-odds of any limitation in 2015 by 27%.
In column 3, the dependent variable is the mean number of ADL
limitations. Drug launches during the 1982e2015 period are esti-
mated to have reduced themean number of ADL limitations in 2015
by 0.136. The mean number of ADL limitations among people with
at least one medical condition was 0.341. This implies that drug
launches during the entire 1982e2015 period reduced the mean
number of ADL limitations in 2015 of people with at least one
medical condition by 29% (¼ 0.136/(0.341 þ .136)).
In column 4, the dependent variable is themean number of IADL
limitations. The estimates indicate that drug launches did not have
a statistically significant effect onmean number of IADL limitations.
In column 5, the dependent variable is the mean CASP index of
quality of life and well-being. The estimate of the drug launch co-
efficient is positive and marginally significant (p-value¼ .075). The
mean CASP index among people with at least one medicaltion drugs on disability in eleven European countries, Disability and
Table 3
Number of drugs launched during 1982e2015, by medical condition and country.
medical condition Austria Belgium Denmark France Germany Greece Italy Portugal Spain Sweden Switzerland mean
C00-C14 cancer oral cavity 2 2 2 2 2 2 2 2 2 2 2 2.0
C15 cancer oesophagus 2 2 2 3 3 2 2 2 2 2 2 2.2
C16 cancer stomach 6 5 5 6 5 5 5 4 4 6 5 5.1
C18-C20 cancer colon or rectum 10 8 9 9 8 6 8 5 7 9 9 8.0
C22 cancer liver 3 3 3 3 3 3 3 2 3 3 3 2.9
C25 cancer pancreas 9 7 8 8 8 7 7 4 7 8 9 7.5
C32 cancer larynx 0 0 0 0 0 0 0 0 0 0 0 0.0
C34 cancer lung 16 13 16 17 16 11 11 9 13 15 14 13.7
C43-C44 cancer skin 12 7 10 10 10 5 8 8 7 10 9 8.7
C50 cancer breast 24 22 22 25 24 21 24 13 23 22 23 22.1
C53 cancer cervix 2 2 2 2 2 2 2 1 2 2 2 1.9
C54.1 cancer endometrium 0 0 0 0 0 0 0 0 0 0 0 0.0
C56 cancer ovary 8 8 8 8 8 7 8 5 8 8 8 7.6
C61 cancer prostate 13 13 13 13 13 10 9 8 12 12 13 11.7
C62 cancer testicle 0 0 0 0 0 0 0 0 0 0 0 0.0
C64 cancer kidney 4 3 4 3 4 3 2 2 3 4 3 3.2
C67 cancer bladder 2 2 2 2 2 2 2 2 2 2 2 2.0
C71 cancer brain 2 2 1 2 1 2 2 0 1 1 1 1.4
C73 cancer thyroid 3 2 3 2 3 1 1 1 1 3 3 2.1
C82-C85 cancer NHL 17 14 15 14 17 10 15 6 13 16 13 13.6
C91-C95 cancer leukaemia 22 17 22 21 24 14 20 8 17 21 20 18.7
E10-E14 diabetes 31 27 30 31 31 30 28 22 30 30 31 29.2
E78 high cholesterol 8 9 8 9 8 9 8 9 8 8 9 8.5
G20 parkinson disease 9 9 9 9 9 9 9 8 9 7 9 8.7
G30 alzheimer 4 4 4 4 4 4 4 4 4 4 4 4.0
H26.9 cataracts 0 0 0 0 0 0 0 0 0 0 0 0.0
I10 hypertension 31 28 29 37 37 32 34 32 32 27 31 31.8
I21-I23 heart attack 19 17 18 17 20 18 19 12 17 16 19 17.5
I63-I64 stroke 8 7 7 7 7 6 6 6 7 7 7 6.8
J40eJ47 chronic lung 23 19 20 22 22 20 21 18 22 21 21 20.8
K25-K27 ulcer 8 8 8 8 8 8 8 8 8 8 8 8.0
M05-M06 rheumatoid arthritis 18 17 18 17 17 17 18 11 19 17 17 16.9
M15-M19 osteoarthritis 7 5 7 8 6 8 8 8 8 6 6 7.0
N18 chronic kidney 10 10 11 10 11 11 11 9 10 11 10 10.4
S72 hip fracture 3 3 3 3 3 3 3 3 3 3 3 3.0
mean 9.6 8.4 9.1 9.5 9.6 8.2 8.8 6.6 8.7 8.9 9.0 8.8
Table 4
Estimates of model of the effect of the number of drug launches and other variables on disability (eq. (2)).
Column 1 2 3 4 5
Dependent variable
Regressor log-odds of severe limitation log-odds of any limitation number of ADL limitations number of IADL limitations CASP index
LAUNCHES_1982_2015 Estimate ¡0.020 ¡0.018 ¡0.008 0.004 0.033
Z ¡2.85 ¡2.13 ¡2.25 0.81 1.78
Pr > jZj 0.004 0.033 0.024 0.415 0.075
ln(PREV) Estimate ¡0.228 ¡0.220 0.038 ¡0.092 0.116
Z ¡3.29 ¡2.97 0.78 ¡2.21 1.05
Pr > jZj 0.001 0.003 0.433 0.027 0.296
AGE_MEAN Estimate 0.042 0.004 0.028 0.076 ¡0.173
Z 3.10 0.21 3.06 5.45 ¡4.39
Pr > jZj 0.002 0.834 0.002 <.0001 <.0001
OVERWEIGHT% Estimate 0.866 0.244 0.031 0.061 0.454
Z 3.12 0.63 0.18 0.20 0.62
Pr > jZj 0.002 0.528 0.855 0.841 0.537
OBESE% Estimate 0.383 0.299 0.370 0.300 ¡3.145
Z 0.90 0.57 1.42 0.89 ¡3.12
Pr > jZj 0.369 0.570 0.155 0.376 0.002
Number of observations 289 273 330 330 327
Estimates in bold are statistically significant (p-value< .05).
Eq. (2): Ydc¼ b0-33 LAUNCHES_1982_2015dc þ g ln(PREVdc) þ r AGE_MEANdc þ L1 OVERWEIGHT%dc þ L2 OBESE%dc þ ad þ pc þ εdc.
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Table 5
Estimated effects of 1982e2015 drug launches on mean 2015 disability of people with at least one medical condition.
Column 1 2 3
Disability measure actual mean counterfactual (no 1982e2015 drug launches) mean effect of 1982e2015 drug launches
probability of severe limitation 16.9% 21.8% 4.9%
probability of any limitation 53.4% 61.1% 7.7%
mean number of ADL limitations 0.34 0.48 0.14
mean CASP index 36.58 37.16 0.58
F.R. Lichtenberg / Disability and Health Journal xxx (xxxx) xxx 9condition was 36.58, so this implies that drug launches during the
entire 1982e2015 period increased the mean CASP index of people
with at least one medical condition by 1.6% (¼ 0.576/36.58).
As discussed above, to allow for the possibility that drugs
launched at different times during 1982e2015 had different effects
on disability in 2015, we also estimated two more general versions
of eq. (2), in which we differentiated between the number of
launches in 3 or 4 periods. Appendix Table 3 provides a comparison
of the estimated impacts of new drug launches on disability in the
three different versions of the model. The magnitudes and signifi-
cance of the estimated effects on each of the disability measures are
almost identical in the three models. This may be attributable to
multicollinearity between the number of launches in different pe-
riods. Amultivariate regressionmodel with collinear predictors can
indicate how well the entire bundle of predictors predicts the
outcome variable, but it may not give valid results about any in-
dividual predictor, or about which predictors are redundant with
respect to others.23
Discussion
Estimates of the effects of 1982e2015 drug launches on the
mean 2015 disability of people with at least one medical condition
are summarized in Table 5. The first column shows the actual mean
values, which are approximately equal to the values for 31 medical
conditions combined in Table 2. The second column shows the
counterfactual mean value, under the (admittedly unrealistic)
assumption that no drugs had been launched during 1982e2015.
The third column shows the difference between the actual and
counterfactual means, i.e. the estimated effect of 1982e2015 drug
launches on the disability measure. The estimates imply that drug
launches during 1982e2015 reduced the probability of severe
limitation in 2015 by 4.9 percentage points, from 21.8% to 16.9%.
They reduced the probability of any limitation in 2015 by 7.7 per-
centage points, from 61.1% to 53.4%.16
Verropoulou and Tsimbos (2017)24 analyzed disability trends
among older adults in ten European countries over 2004e2013,
using various indicators and Survey of Health, Ageing and Retire-
ment in Europe (SHARE) data, and did not detect any significant
trend in severe disability. However, the reduction in disability
attributable to increasing availability of prescription drugs may
have been offset by adverse trends in behavioral risk factors, such as
obesity. SHARE data indicate that the fraction of the population
aged 50 and over that was obese (BMI 30) increased from 17.1% in
2004 to 22.2% in 2015.
Comparison of the benefit, in terms of 2015 disability reduction,
of 1982e2015 drug launches to the cost of these drugs in 2015 may
be of interest. Data published by the International Federation of
Pharmaceutical Manufacturers & Associations on pharmaceutical
expenditure in the eleven countries in 2014 (2015 data are not16 Combining these estimates implies that drug launches during 1982e2015
reduced the probability of mild limitation in 2015 by 2.9 percentage points, from
39.4% to 36.5%.
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average pharmaceutical expenditure was $667. Data from IQVIA
for 9 of the 11 countries17 indicate that just over half (52%) of
pharmaceutical expenditure was on drugs launched after 1981, so
we estimate that population-weighted average pharmaceutical
expenditure on drugs launched after 1981 was $345 (¼ 52% * $667).
This represents average expenditure for the entire population, i.e.
for all age groups. Data on pharmaceutical expenditure by age
group are not available for these countries, but they are available for
the U.S. According to the U.S. Medical Expenditure Panel Survey, in
2014 in the U.S., mean pharmaceutical expenditure of people 45
and over was 77% higher than mean pharmaceutical expenditure of
the entire population. Hence it seems reasonable to estimate that
mean pharmaceutical expenditure on drugs launched after 1981 by
people 45 and over in the eleven European countries was $611 (¼
1.77 * $345). Expenditure of $611 reduced the probability of being
severely limited by 4.9 percentage points. If people would have
been willing to pay at least $12,469 (¼ $611/4.9%) to avoid being
severely limited, drugs launched during 1982e2015 would have
been cost-effective, even if they did not provide any other benefits,
e.g. increased longevity and reduced hospitalization. However
previous research11,13 has demonstrated that new drug launches
have also provided those benefits.
Our analysis is subject to several limitations. Our measure of
access to prescription drugs (the number of drugs previously
launched in a country) is imperfect. Launch of a drug is a necessary
condition for access, not a sufficient condition. Our drug launch
data are left-censoreddonly drugs launched anywhere in the
world after 1981 are captured. Our analysis did not account for off-
label uses of a drug. Our drug indications datawere obtained from a
French database, and some drugs launched in other countries have
not been launched in France. Our estimates control for the effects
on disability of a country's overall health system and macroeco-
nomic conditions, to the extent that those effects don't vary across
diseases, but those effects might vary across diseases. The effects of
targeted efforts and programs to reduce disease burden may be
imperfectly controlled for by including disease prevalence in the
disability models. Our data enabled us to measure the average
disability of people with a medical condition, not the average
disability of people caused by a medical condition. Future research
may enable these limitations to be superseded.Conclusion
Access to prescription drugs varies across countries. Even when
the total number of drugs launched in two countries is similar, the
specific drugs that were launched, and the diseases those drugs are
used to treat, may differ.
We used data on 31 diseases in eleven European countries,
partially derived from the Survey of Health, Ageing and Retirement
in Europe, to test the hypothesis that the larger the relative number17 Data for 2 small countries (Denmark and Greece) were not available.
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country, the lower the relative disability of patients aged 50 and
over with that disease in that country, controlling for the average
level of disability (and the average number of drug launches) in that
country and from that disease, and for the number of patients with
the disease and their mean age.
The estimates imply that drug launches during 1982e2015
reduced the probability of severe limitation in 2015 by 4.9 per-
centage points, from 21.8% to 16.9%; they reduced the probability of
any limitation by 7.7 percentage points, from 61.1% to 53.4%; and
they reduced the mean number of Activities of Daily Living limi-
tations by about 29%. Drug launches also yielded a small increase in
an index of quality of life and well-being.
Previous research has demonstrated that new drug launchesAppendix Table 1
Number of SHARE Wave 6 respondents who reported that they had each medical condit
cause Austria Belgium Denmark France Germ
C00-C14 cancer oral cavity 0 3 2 2 4
C15 cancer oesophagus 1 2 3 2 1
C16 cancer stomach 1 8 2 1 12
C18-C20 cancer colon or rectum 16 40 17 21 22
C22 cancer liver 4 6 5 5 9
C25 cancer pancreas 1 2 1 2 6
C34 cancer lung 6 17 12 15 8
C43-C44 cancer skin 24 25 17 8 49
C50 cancer breast 33 76 23 59 55
C53 cancer cervix 8 16 4 8 8
C56 cancer ovary 4 8 7 2 3
C61 cancer prostate 19 45 33 35 53
C64 cancer kidney 2 5 4 12 11
C67 cancer bladder 7 11 2 9 22
C71 cancer brain 2 6 2 4 5
C73 cancer thyroid 0 6 2 9 8
C82-C85 cancer NHL 5 10 10 4 10
C91-C95 cancer leukaemia 5 9 8 7 6
E10-E14 diabetes 439 645 282 451 613
E78 high cholesterol 716 1724 883 872 791
G20 parkinson disease 30 50 21 33 37
G30 alzheimer 130 106 37 70 74
I10 hypertension 1462 1944 1253 1268 1850
I21-I23 heart attack 410 553 313 490 447
I63-I64 stroke 212 199 114 134 160
J40eJ47 chronic lung 217 414 296 250 351
K25-K27 ulcer 115 327 88 119 91
M05-M06 rheumatoid arthritis 385 389 102 124 522
M15-M19 osteoarthritis 230 1866 867 1391 945
N18 chronic kidney 53 96 39 71 95
S72 hip fracture 36 121 47 81 67
Mean 148 282 145 179 204
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died if the drugs had not been launched to remain alive. Presum-
ably, those additional survivors were the most severely ill and
disabled: biomedical innovation tends to offset natural selection.
Therefore, the reduction in the average disability of living people
due to new drug launches would probably have been greater if the
drugs had not reduced mortality.Funding
Financial support for this researchwas provided by Novartis and
by Interpharma.ion, by country
any Greece Italy Portugal Spain Sweden Switzerland Mean
0 6 1 5 1 3 2
2 0 0 3 0 1 1
5 18 6 9 7 2 6
12 7 10 24 20 5 18
7 8 2 8 4 4 6
1 11 1 2 3 1 3
13 14 4 15 5 7 11
5 1 2 8 12 9 15
31 71 31 49 42 25 45
4 4 5 2 3 2 6
4 14 4 5 5 2 5
25 22 15 41 58 23 34
7 9 2 9 4 0 6
6 3 7 9 5 1 7
2 7 0 7 2 2 4
11 12 4 5 0 0 5
4 0 2 1 9 5 5
1 2 3 5 12 2 5
654 628 363 1003 412 227 520
1518 1206 709 1622 587 452 1007
56 41 13 74 30 20 37
94 108 52 286 75 25 96
2046 2111 827 2351 1477 849 1585
550 473 187 570 406 182 416
155 159 90 140 165 43 143
282 275 137 358 176 127 262
347 152 135 155 65 32 148
414 353 196 926 82 110 328
679 793 244 612 622 609 805
46 94 65 106 31 24 65
132 73 40 122 106 35 78
229 215 102 275 143 91
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Appendix Table 2 (continued )
Parameter Estimate Std. Err. Z Pr> jZj
Sweden 0.428 0.057 7.53 <.0001
Switzerland 0.000 0.000 . .
C00-C14 cancer oral cavity 0.305 0.211 1.45 0.147
C15 cancer oesophagus 0.868 0.219 3.96 <.0001
C16 cancer stomach 0.051 0.181 0.28 0.776
C18-C20 cancer colon or rectum 0.156 0.156 1.00 0.320
C22 cancer liver 0.418 0.233 1.80 0.072
C25 cancer pancreas 0.034 0.236 0.14 0.887
C32 cancer larynx 0.586 0.274 2.14 0.032
C34 cancer lung 0.649 0.209 3.10 0.002
C43-C44 cancer skin 1.001 0.171 5.86 <.0001
C50 cancer breast 0.051 0.221 0.23 0.818
C53 cancer cervix 0.068 0.196 0.35 0.727
C54.1 cancer endometrium 0.838 0.193 4.34 <.0001
C56 cancer ovary 0.053 0.225 0.24 0.813
C61 cancer prostate 0.661 0.120 5.51 <.0001
C62 cancer testicle 1.072 0.253 4.24 <.0001
C64 cancer kidney 1.329 0.202 6.58 <.0001
C67 cancer bladder 0.452 0.165 2.75 0.006
C71 cancer brain 0.360 0.222 1.62 0.105
C73 cancer thyroid 1.140 0.215 5.31 <.0001
C82-C85 cancer NHL 0.092 0.231 0.40 0.689
C91-C95 cancer leukaemia 0.523 0.271 1.93 0.053
E10-E14 diabetes 0.028 0.216 0.13 0.895
E78 high cholesterol 0.745 0.187 3.99 <.0001
G20 parkinson disease 0.537 0.087 6.20 <.0001
G30 alzheimer 1.067 0.091 11.75 <.0001
H26.9 cataracts 0.720 0.104 6.94 <.0001
I10 hypertension 0.143 0.263 0.55 0.585
I21-I23 heart attack 0.125 0.133 0.94 0.349
I63-I64 stroke 0.560 0.055 10.27 <.0001
K25-K27 ulcer 0.444 0.134 3.31 0.001
M05-M06 rheumatoid arthritis 0.071 0.143 0.50 0.618
M15-M19 osteoarthritis 0.173 0.171 1.02 0.310
N18 chronic kidney 0.071 0.081 0.88 0.379
S72 hip fracture 0.000 0.000 . .
Intercept 3.560 1.084 3.28 0.001
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Comparison of estimated effects of drug launches on disability when drug launches are categorized into 1, 3, and 4 periods
Dependent variable No. of launch periods Mean Estimate Standard Error Chi-Square Pr> ChiSq
log-odds of severe limitation 1 0.317 0.111 8.12 0.004
3 0.301 0.122 6.11 0.013
4 0.327 0.126 6.75 0.009
log-odds of any limitation 1 0.317 0.149 4.54 0.033
3 0.282 0.141 3.97 0.046
4 0.304 0.142 4.60 0.032
number of ADL limitations 1 0.136 0.060 5.07 0.024
3 0.144 0.056 6.65 0.010
4 0.144 0.054 7.27 0.007
number of IADL limitations 1 0.072 0.088 0.66 0.415
3 0.078 0.100 0.61 0.434
4 0.079 0.085 0.85 0.357
CASP index 1 0.576 0.324 3.16 0.075
3 0.641 0.376 2.91 0.088
4 0.573 0.323 3.15 0.076
no. of launch periods
1 b0-33 * mean(LAUNCHES_1982_2015dc)
3 (b0-9 * mean(LAUNCHES_2006_2015dc)) þ (b10-19 * mean(LAUNCHES_1996_2005dc)) þ (b20-33 * mean(LAUNCHES_1982_1995dc))
4 (b0-4 * mean(LAUNCHES_2011_2015dc)) þ (b5-9 * mean(LAUNCHES_2006_2010dc)) þ (b10-14 * mean(LAUNCHES_2001_2005dc)) þ (b15-33 *
mean(LAUNCHES_1982_2000dc))
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Appendix Table 4
2014 Pharmaceutical expenditure, by country
Country TOTAL PHARMACEUTICAL SALES (USD BILLION) PHARMACEUTICAL SALES (USD PER CAPITA) Population (millions)
Austria $8.1 $951 8.5
Belgium $7.7 $689 11.2
Denmark $3.8 $675 5.6
France $44.7 $697 64.1
Germany $68.9 $667 103.2
Greece $6.6 $598 11.0
Italy $35.3 $591 59.8
Portugal $4.6 $437 10.4
Spain $32.8 $709 46.2
Sweden $5.5 $566 9.7
Switzerland $7.7 $939 8.2
TOTAL $225.6 $667 338.1
Source: International Federation of Pharmaceutical Manufacturers & Associations (2017).
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